[1]董 曼,王月莉.不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响[J].陕西医学杂志,2021,50(6):657-659,663.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
　DONG Man,WANG Yueli.Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome[J].,2021,50(6):657-659,663.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.004]
点击复制

不同剂量地西他滨对骨髓增生异常综合征小鼠Beclin1蛋白表达的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年6期
页码:
657-659,663
栏目:
基础研究
出版日期:
2021-06-05

文章信息/Info

Title:
Effects of different doses of decitabine on Beclin1 protein expression in mice with myelodysplastic syndrome
作者:
董 曼; 王月莉
(铜川市人民医院血液科,陕西 铜川 727100)
Author(s):
DONG Man; WANG Yueli
(Department of Hematology,Tongchuan People's Hospital,Tongchuan 727100,China)
关键词:
骨髓增生异常综合征;  剂量;  模型;  地西他滨;  小鼠;  Beclin1蛋白表达
Keywords:
Myelodysplastic syndrome;  Dose;  Model;  Decitabine;  Mice;  Beclin1 protein expression
分类号:
R 551.3
DOI:
DOI:10.3969/j.issn.1000-7377.2021.06.004
文献标志码:
A
摘要:
目的:探讨不同剂量地西他滨对骨髓增生异常综合征(MDS)小鼠Beclin1蛋白表达的影响。方法:选择36只NOD/SCID小鼠制备MDS小鼠模型后,随机分为模型组、低剂量组和高剂量组,每组12只。模型组、低剂量组、高剂量组隔天于腹腔内分别注射5 mg/kg生理盐水、5 mg/kg地西他滨、10 mg/kg地西他滨,治疗28 d。比较三组小鼠体重、红细胞(RBC)、白细胞(WBC)、血小板(PLT)以及Beclin1蛋白表达情况。结果:治疗后,低剂量组和高剂量组小鼠第14、28天体重、RBC、WBC、PLT高于模型组(均P<0.05),CD45+细胞比例低于模型组(P<0.05),第28天小鼠肝、脾组织Beclin1蛋白相对表达水平高于模型组(均P<0.05),而低剂量组与高剂量组上述指标比较差异无统计学意义(均P>0.05)。结论:低剂量地西他滨即可提高MDS小鼠Beclin1蛋白表达水平,抑制增殖与浸润,从而促进小鼠外周血与体重恢复正常。
Abstract:
Objective:To investigate the effects of different doses of decitabine on the expression of Beclin1 in mice with myelodysplastic syndrome(MDS).Methods:After selecting 36 NOD/SCID mice to prepare MDS mouse models,they were randomly divided into model group,low-dose group and high-dose group,with 12 mice in each group.The model group,the low-dose group,and the high-dose group were injected intraperitoneally with 5 mg/kg saline,5 mg/kg decitabine,and 10 mg/kg decitabine respectively every other day for 28 days of treatment.The weight,red blood cell(RBC),white blood cell(WBC),platelet(PLT)and Beclin1 expression of the three groups were compared.Results:After treatment,the body weight,RBC,WBC,and PLT of mice in the low-dose group and high-dose group were higher than those in the model group on the 14th and 28th days(all P<0.05),and the ratio of CD45+ cells was lower than that in the model group(P<0.05),and the relative expression levels of Beclin1 in the liver and spleen tissues of mice on the 28th day were higher than those in the model group(all P<0.05),but there was no significant difference in the above indicators between the low-dose group and the high-dose group(all P>0.05).Conclusion:The application of low-dose decitabine can increase the expression level of Beclin1 in mice with MDS,inhibit proliferation and infiltration,and promote the recovery of peripheral blood and body weight in mice.

参考文献/References:

[1] 聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外周血中的表达及临床意义[J].陕西医学杂志,2019,48(8):977-980.
[2] 刘 欣,刘艳芬,孙 旭,等.血速升颗粒联合复方黄黛片治疗骨髓增生异常综合征化疗相关血细胞减少临床研究[J].陕西中医,2021,42(1):78-80.
[3] 周玉才,孙长勇,王茂生,等.参芪扶正注射液对MDS患者血清叶酸、VB12及EPO的影响[J].陕西中医,2017,38(5):605-606.
[4] 田雪姣,徐 颖.地西他滨联合CAG方案治疗老年初治急性髓系白血病的效果[J].河南医学研究,2021,30(1):86-88.
[5] 张 媛,陈 鹏,李慧敏,等.地西他滨联合HA方案诱导治疗老年急性髓系白血病疗效观察[J].中国医刊,2021,56(1):91-93.
[6] 孙兴卫.地西他滨治疗成人急性髓细胞白血病的临床效果[J].药品评价,2020,17(8):59-61.
[7] Flotho C,Sommer S,Lübbert M.DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia[J].Semin Cancer Biol,2018,51(15):68-79.
[8] Cazzola M.Myelodysplastic syndromes[J].N Engl J Med,2020,383(14):1358-1374.
[9] Germing U,Schroeder T,Kaivers J,et al.Novel therapies in low- and high-risk myelodysplastic syndrome[J].Expert Rev Hematol,2019,12(10):893-908.
[10] Kubasch AS,Platzbecker U.Beyond the edge of hypomethylating agents:Novel combination strategies for older adults with advanced MDS and AML[J].Cancers(Basel),2018,10(6):113-119.
[11] Montoro J,Yerlikaya A,Ali A,et al.Improving treatment for myelodysplastic syndromes patients[J].Blood,2018,19(12):66.
[12] Odenike O.Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents[J].Hematology Am Soc Hematol Educ Program,2017,2017(1):460-469.
[13] Schroeder T,Rautenberg C,Haas R,et al.Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation[J].Int J Hematol,2018,107(2):138-150.
[14] 董 杨,邓来军,展昭民,等.地西他滨联合小剂量米托蒽醌预激方案治疗老年急性髓系白血病的疗效及安全性研究[J].中国实用内科杂志,2020,40(7):567-570.
[15] 陈园园,石 锐,郭素青,等.地西他滨治疗伴DNA甲基转移酶基因突变的骨髓增生异常综合征患者的疗效分析[J].中国实验血液学杂志,2020,28(4):1292-1297.
[16] Aleshin A,Greenberg PL.Molecular pathophysiology of the myelodysplastic syndromes:Insights for targeted therapy[J].Blood Adv,2018,2(20):2787-2797.
[17] Bewersdorf JP.Evolving therapies for lower-risk myelodysplastic syndromes[J].Am J Hematol,2020,99(4):677-692.
[18] Bond DR,Lee HJ,Enjeti AK.Unravelling the epigenome of myelodysplastic syndrome:Diagnosis,prognosis,and response to therapy[J].Cancers,2020,12(11):3128.
[19] 祖璎玲,周 健,张龚莉,等.地西他滨联合化疗治疗复发/难治性T细胞淋巴瘤/白血病3例并文献复习[J].临床血液学杂志,2020,33(3):211-214.
[20] 叶吉明,辜学忠,储雨妍,等.地西他滨和沙利度胺两种方案治疗骨髓增生异常综合征的临床疗效[J].昆明医科大学学报,2020,41(3):72-76.
[21] Steensma DP.Myelodysplastic syndromes current treatment algorithm 2018[J].Blood Cancer J,2018,8(5):47.
[22] Steensma D.Does early diagnosis and treatment of myelodysplastic syndromes make a difference?[J].Best Pract Res Clin Haematol,2019,32(4):101099.
[23] Zeidan AM,Santini V.How I treat MDS after hypomethylating agent failure?[J].Ann Hematol,2019,133(6):521-529.

相似文献/References:

[1]聂泽强,李晓云,马爻芳,等.WT1基因在骨髓增生异常综合征患者外同血中的表达及临床意义[J].陕西医学杂志,2019,(8):977.
　NIE Zeqiang,LI Xiaoyun,MA Yaofang,et al.Expression of WT1 gene in patients with Myelodysplastic syndrome[J].,2019,(6):977.
[2]叶久敏,卿 忠,杨 光,等.不同浓度右美托咪定联合罗哌卡因腘动脉与膝关节后囊间隙阻滞用于全膝关节置换镇痛临床研究[J].陕西医学杂志,2020,49(8):1020.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.027]
　YE Jiumin,QING Zhong,YANG Guang,et al.Clinical study on analgesia of different concentrations of dexmedetomidine combined with ropivacaine for IPACK block in total knee arthroplasty[J].,2020,49(6):1020.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.027]
[3]栾百婷,罗 涛,程洪瑜,等.脑出血患者穿刺引流术后尿激酶应用剂量和时间研究*[J].陕西医学杂志,2020,49(11):1399.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.008]
　LUAN Baiting,LUO Tao,CHENG Hongyu,et al.Study on the dose and timing of the application of urokinase after puncture drainage in patients with intracerebral hemorrhage[J].,2020,49(6):1399.[doi:DOI:10.3969/j.issn.1000-7377.2020.11.008]
[4]李振波,陆 诚.阿扎胞苷治疗骨髓增生异常综合征合并额外性梳样蛋白1基因突变疗效及安全性分析[J].陕西医学杂志,2021,50(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
　LI Zhenbo,LU Cheng.Efficacy and safety of azacitidine in treatment of MDS with ASXL1 gene mutation[J].,2021,50(6):1135.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.023]
[5]李荣芳,金 龙,赵立丹.外周血T细胞免疫球蛋白黏蛋白-3和血清乳酸脱氢酶联合检测在骨髓增生异常综合征诊断中的应用价值[J].陕西医学杂志,2021,50(9):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
　LI Rongfang,JIN Long,ZHAO Lidan.Application value of combined detection of peripheral blood TIM-3 and serum LDH in diagnosis of MDS[J].,2021,50(6):1143.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.025]
[6]刁云霞,孙晓妮,李思远.麻醉诱导期不同剂量舒芬太尼在儿童扁桃体摘除术中的应用效果及安全性观察[J].陕西医学杂志,2022,51(6):692.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.012]
　DIAO Yunxia,SUN Xiaoni,LI Siyuan.Application effect and safety of different doses of sufentanil during anesthesia induction in children undergoing tonsillectomy[J].,2022,51(6):692.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.012]
[7]王美佳,刘虹伶,曾依伶.地西他滨联合HA方案治疗骨髓增生异常综合征疗效及安全性研究[J].陕西医学杂志,2023,52(12):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
　WANG Meijia,LIU Hongling,ZENG Yiling.Efficacy and safety of decitabine combined with harringtonine and cytarabine regimen in treatment of myelodysplastic syndrome[J].,2023,52(6):1731.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.023]
[8]常娟娟,李太平,康婉英,等.容积旋转调强与调强放疗在宫颈癌放疗中的应用及剂量学、安全性研究[J].陕西医学杂志,2024,(2):194.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.010]
　CHANG Juanjuan,LI Taiping,KANG Wanying,et al.Application,dosimetric and safety analysis of volumetric modulated arc therapy and intensity modulated radiation therapy in radiotherapy of cervical cancer[J].,2024,(6):194.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.010]
[9]马丽丽,付长江.存活素和细胞周期素依赖性蛋白激酶抑制因子2B在骨髓增生异常综合征诊断及患者预后评估中的临床价值研究[J].陕西医学杂志,2024,(3):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]
　MA Lili,FU Changjiang.Clinical value of Survivin and P15INK4B in diagnosis of myelodysplastic syndrome and prognosis evaluation of patients[J].,2024,(6):348.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.013]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2021SF-312)
更新日期/Last Update: 2021-06-07